For patients with unresectable or metastatic HER2 negative G/GEJ cancer, zolbetuximab (Vyloy™, Astellas) can be offered as first-line treatment providing the tumour is CLDN18.2 positive. In clinical trials as SPOTLIGHT and GLOW, about 38% of patients were categorized as CLDN18.2 positive, defined as ≥75% of tumor cells demonstrating moderate to strong membranous CLDN18 immunohistochemical staining reaction.

The pilot run for CLDN18.2 will be free of charge for participants within the Companion Module run C17. Other participants can contact NordiQC for free admission to this pilot run. Please note that number of participants is limited to 75 and based on “first-come, first-served”. UPDATE: Limit of 75 has been reached.